Pulmonary Effects of Methotrexate
Methotrexate can be safely used in rheumatoid arthritis patients with mild and stable lung disease, but carries a risk of acute hypersensitivity pneumonitis (methotrexate pneumonitis) that occurs unpredictably in approximately 3% of patients, independent of dose or duration of therapy. 1
Key Pulmonary Side Effects
Acute Methotrexate Pneumonitis
- Incidence: 3.2% in long-term low-dose therapy 2
- Onset: Unpredictable—can occur at any time during treatment, regardless of cumulative dose or duration 3
- Clinical presentation: Acute onset of dyspnea, dry cough, fever, and hypoxemia 3
- Risk factors: Preexisting lung disease increases risk, though the magnitude is uncertain 1
Chronic Pulmonary Effects
No evidence supports chronic interstitial lung disease from low-dose methotrexate. A 2-year prospective study with serial HRCT scans and pulmonary function tests found no difference in pulmonary fibrosis rates (20% vs 23%) or lung function decline between methotrexate-treated and control RA patients 4. Minor subclinical decreases in FVC (-2.2%) and FEV1 (-5.0%) have been observed but are not clinically significant 2.
Use in Patients with Preexisting Lung Disease
The 2021 ACR guidelines conditionally recommend methotrexate over alternative DMARDs even for patients with mild and stable airway or parenchymal lung disease 1. This recommendation prioritizes methotrexate's critical role as anchor therapy in RA, acknowledging that:
- Alternative DMARDs also carry lung toxicity risks
- The absolute risk of worsening lung disease is uncertain
- No alternatives offer similar efficacy with superior safety profiles
Critical caveat: Patients must be informed of their increased pneumonitis risk before starting therapy 1. Recent 2024 evidence from France and a 2025 systematic review support this approach, finding no increased ILD risk with methotrexate in RA-ILD patients 5, 6.
Monitoring Strategy
Baseline Assessment (Mandatory)
Additional Baseline Tests (Recommended)
- Pulmonary function tests with DLCO if patient has respiratory history or current symptoms 7
- This establishes baseline but does not predict who will develop pneumonitis 2
During Treatment
Do NOT perform routine serial pulmonary function tests—they cannot detect methotrexate pneumonitis before clinical symptoms appear 2. A prospective study of 124 patients found no significant decrease in pulmonary parameters preceding acute pneumonitis 2.
Instead, monitor clinically:
- Monthly visits during first 3 months, then every 1-2 months 3
- Educate patients to report respiratory symptoms immediately (dyspnea, dry cough, fever) 3
- Maintain high index of suspicion for new respiratory complaints
Management of Suspected Pneumonitis
Immediate Actions
- Stop methotrexate immediately 7
- Evaluate severity urgently—admit or obtain immediate pulmonology consultation if serious disease suspected 7
- Rule out infection first—consider bronchoscopy with BAL to exclude opportunistic infections (Pneumocystis, bacterial) 8
Treatment
- Leucovorin calcium rescue if severe toxicity 3
- Corticosteroids for confirmed methotrexate pneumonitis 8
- Supportive care including oxygen, hydration
- Most cases resolve with drug discontinuation alone or with corticosteroids 8
Prognosis
- Rapid regression typical with appropriate management 8
- Fatalities have occurred, particularly in elderly or frail patients 9
- Reintroduction of methotrexate does not guarantee recurrence, but should only be considered if no alternative exists 8
Important Clinical Pitfalls
Do not rely on serum methotrexate levels—they show inconsistent association with adverse reactions at low doses and cannot predict toxicity 9.
Asian populations may have higher risk—multiple studies from East Asia report increased RA-ILD risk with methotrexate, suggesting possible genetic susceptibility 6. However, the 2025 systematic review of 47,271 patients found most evidence does not support increased risk 6.
Avoid NSAIDs with high-dose methotrexate—though standard RA doses (7.5-15 mg/week) are typically safe with concurrent NSAIDs, higher doses risk severe toxicity from reduced tubular secretion 3.